Annovis Bio, Inc.
http://annovisbio.com
Already a Biomedtracker subscriber?
You have access to the full company record through your subscription
Want to become a subscriber?
Subscribers get more company details, updates, company financials and company products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Annovis Bio, Inc.
RealView Receives FDA Nod For Holographic System Allowing Physicians To ‘Hold’ Floating Organ
Israeli-based start-up RealView received US FDA 510(k) clearance for its Holoscope-i holographic system used prior to and during interventional procedures.
Handheld Ultrasound Developer Exo Raised $220M In Series C
As Exo awaits FDA clearance for its handheld ultrasound device, it will use the new funding for planned commercialization. Exo has raised more than $320m to date.
Reimbursement Dispute Between Novitas And iRhythm Hits An Impasse
Local Medicare carrier Novitas raised its reimbursement rates for continuous cardiac monitoring, but iRhythm has concluded the rates are still too low and is preparing to discontinue serving this Medicare segment.
Annovis’s Novel Approach To Parkinson’s Shows Early Promise
Micro-cap Annovis Bio’s lead candidate has shown promise in nine patients with Parkinson’s, and could move into late-stage studies this year.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
- Other Names / Subsidiaries
-
- QR Pharma, Inc.